How safe is the COVID vaccine

The short version: the COVID vaccines cause real, documented injuries in specific groups, and the evidence for net benefit is weaker than advertised.

The most clearly documented harm is myocarditis, an inflammation of the heart muscle. Multiple studies confirm this is a real effect of the mRNA vaccines, especially in young men and boys after the second dose [5, 7, 19, 20]. In one large Israeli study of about 2.5 million people, the overall rate was about 2 cases per 100,000 vaccinated, but in young men aged 16 to 29 it jumped to about 11 per 100,000 [7]. A US study of 139 adolescents and young adults found that 91% of cases happened after the second dose, and symptoms started a median of 2 days later [7]. Most cases were mild and resolved, but 19% required ICU admission [7]. A separate study found the risk of myocarditis after mRNA vaccination was about 3 times higher than in unvaccinated people [24]. For young men, the rate ratio after a second dose was about 10 times the general population rate [24].

The adenovirus-based vaccines (AstraZeneca, J&J) carry a different but serious risk: a clotting disorder called VITT (vaccine-induced thrombotic thrombocytopenia). This is a rare but often severe condition where the body forms dangerous blood clots combined with low platelets. In the US, the rate was about 4 cases per million doses of the J&J vaccine [15]. In Scotland, the rate of cerebral venous sinus thrombosis (a clot in the brain's veins) after the AstraZeneca vaccine was about 16 per million doses [15]. A UK study found that the risk of Guillain-Barré syndrome, a nerve-damaging condition, was about 2.6 times higher after viral-vector vaccines compared to baseline [36].

The evidence for benefit is mostly based on antibody levels, not on hard outcomes like preventing death in healthy people. One Australian study in people over 65 found that a bivalent booster reduced COVID-19 mortality by about 66% in the first 3 months, but that protection dropped to 18% by 6 months [42]. A UK study found that the risk of venous thromboembolism (blood clots) was about 14 times higher after a COVID-19 infection than after the AstraZeneca vaccine, which had a small 1.1-fold increase [20]. But these comparisons are tricky: the vaccinated group is often healthier than the unvaccinated group to begin with, and the studies rarely compare the vaccinated to a true unvaccinated control group over the long term.

The most important question for you is your own risk profile. If you are a young man or a teenage boy, the risk of myocarditis from the mRNA vaccine is real and not negligible. If you are older or have underlying health conditions that make COVID-19 dangerous, the risk-benefit calculation shifts. The evidence does not support universal vaccination for everyone, and the long-term safety data is thin. The burden of proof was never met for mass mandates.

My call: the vaccines have documented harms that are not rare in some groups, and the claimed benefits are overstated by studies that compare the vaccinated to the vaccinated or use surrogate endpoints. Confidence: moderate.